CSCs plasticity in colon cancer has been well documented; as a consequence, targeted ablation of Lgr5+ cells is not sufficient to eradicate tumours as other cells can revert to Lgr5+ CSCs and contribute to tumour re-growth upon an initial regression40,42,43. The gene discussed is LGR5; the disease is colonic neoplasm.